Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study. The post Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug appeared first on Investor's Business Daily.
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
The post Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
